PCT, spin and statistics, and analytic wave front set

A new, more general derivation of the spin-statistics and PCT theorems is presented. It uses the notion of the analytic wave front set of (ultra)distributions and, in contrast to the usual approach, covers nonlocal quantum fields. The fields are defined as generalized functions with test functions of compact support in momentum space. The vacuum expectation values are thereby admitted to be arbitrarily singular in their space-time dependence. The local commutativity condition is replaced by an asymptotic commutativity condition, which develops generalizations of the microcausality axiom previously proposed.Comment: LaTeX, 23 pages, no figures. This version is identical to the original published paper, but with corrected typos and slight improvements in the exposition. The proof of Theorem 5 stated in the paper has been published in J. Math. Phys. 45 (2004) 1944-195

Towards a Generalized Distribution Formalism for Gauge Quantum Fields

We prove that the distributions defined on the Gelfand-Shilov spaces, and hence more singular than hyperfunctions, retain the angular localizability property. Specifically, they have uniquely determined support cones. This result enables one to develop a distribution-theoretic techniques suitable for the consistent treatment of quantum fields with arbitrarily singular ultraviolet and infrared behavior. The proofs covering the most general case are based on the use of the theory of plurisubharmonic functions and Hormander's estimates.Comment: 12 p., Department of Theoretical Physics, P.N.Lebedev Physical Institute, Leninsky prosp. 53, Moscow 117924, Russi

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the “established CV disease” (CVD) and “CV risk factor” subgroups. The SUSTAIN 6 and PIONEER 6 trials of semaglutide used different criteria for established CVD from those used in REWIND. The present post hoc analysis assessed the effect of semaglutide on major adverse CV events (MACE) in a pooled population of SUSTAIN 6 and PIONEER 6 patients, re-categorized into CV risk subgroups using the REWIND CVD criteria. In the pooled analysis (n = 6480), a lower percentage of patients were in the established CVD subgroup, when using the REWIND CVD criteria, compared with the original trial CVD criteria (66.5% vs. 83.8%, respectively). After re-categorization, the risk of MACE was significantly lower with semaglutide versus placebo in the established CVD subgroup (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.59, 0.92) and nonsignificantly lower in the CV risk factor subgroup (HR 0.84, 95% CI 0.55, 1.28) (P-interaction = 0.60). These results suggest that the CV effects of semaglutide may extend to patients with type 2 diabetes across the CV risk continuum